Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sabatolimab + azacitidine + venetoclax in high/very high risk MDS
2020-003669-21Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sabatolimab in myelodysplastic syndrome (MDS), sponsored by Novartis. Primary endpoint: Safety run-in primary endpoints (Cohort 1 and Cohort 2 of Part 1). Started Feb 2021; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-003669-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003669-21.